US-FDA approves Johnson & Johnson first and only drug-based treatment for children fighting against chronic graft vs. host diseases
IMBRUVICA has become the first FDA-approved therapy for these younger patients who previously had no approved treatment options for this life-threatening disease. Chronic graft vs. host condition can occur after a stem cell or bone marrow transplant when newly transplanted donor cells attack the transplant recipient’s body. Symptoms of the disease can include skin rashes, mouth sores, dry eyes, liver inflammation, development of scar tissue in the skin and joints, and damage to the lungs. This milestone marks the first pediatric indication for the drug and the subsequent introduction of a new oral suspension formulation for patients aged under-12. The FDA-Approved drug can be sold in more than 100 countries and has been capable of treating more than 300,000 child patients worldwide
About Ingenious e-Brain Solutions:-
Ingenious e-Brain Solutions provides high-quality, customized and cost-effective Technology Research, Business Research, and Intellectual Property Research solutions to industry leaders, and innovative companies across the globe. Innovation, knowledge and transparency form the basis of our company’s mission and vision. Along with cost benefits, we provide highest quality results ensuring fool-proof confidentiality and security. We are an ISO certified company with offices in India and USA.
Ingenious e-Brain Solutions has a strong team of analysts, and subject matter experts with domain proficiency which is devoted to help clients grow. Our highly qualified professionals offer tailored, value-added and cost-effective services to our clients. We believe in building long term relationships with our clients who include national and international corporations, Fortune 500 companies, world’s leading research institutes and universities as well as independent inventors.
Get in Touch:-
207-208 Welldone TechPark, Sohna Road
Sector 48, Gurugram,Haryana 122018, India
+91 124 429 4218